Rashmi Ramasubbaiah, MD
Hematology & Oncology · Cameron Park, CANPI 1326202540
Payments from drug & device makers
Across 265 payments — averaging $20.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- E.r. Squibb & Sons, L.L.C.$556
- Pfizer$480
- Johnson & Johnson$368
- Amgen$355
- Genentech USA, Inc.$256
- plus $2K from 33 others
What the payments were for
- Food & beverage$3,60266%
- Education$4989%
- Other$1,37925%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 30 | $1,634 |
| E.r. Squibb & Sons, L.L.C. | 31 | $556 |
| Pfizer | 37 | $480 |
| Johnson & Johnson(2 entities) | 42 | $368 |
| Amgen | 18 | $355 |
| Genentech USA, Inc. | 18 | $256 |
| Astellas Pharma US Inc | 5 | $229 |
| Merck | 11 | $204 |
| AstraZeneca(2 entities) | 6 | $124 |
| Incyte Corporation | 6 | $118 |
| Sanofi | 6 | $116 |
| Seagen Inc. | 7 | $109 |
| Bristol Myers Squibb | 6 | $103 |
| AbbVie | 4 | $78 |
| Array Biopharma Inc | 3 | $78 |
| Gilead | 3 | $70 |
| GSK | 3 | $65 |
| Beigene USA, Inc. | 3 | $53 |
| Mirati Therapeutics, Inc. | 2 | $47 |
| Exelixis Inc. | 2 | $41 |
| Acrotech Biopharma Inc. | 3 | $38 |
| Regeneron Healthcare Solutions, Inc. | 1 | $36 |
| Blueprint Medicines Corporation | 2 | $33 |
| Tersera Therapeutics LLC | 1 | $26 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $24 |
| Tolmar Pharmaceuticals, Inc. | 1 | $24 |
| Servier Pharmaceuticals LLC | 1 | $21 |
| Clovis Oncology, Inc. | 1 | $21 |
| Myovant Sciences Inc. | 1 | $19 |
| Eisai Inc. | 1 | $19 |
| Stemline Therapeutics Inc. | 1 | $18 |
| Foundation Medicine, Inc. | 1 | $17 |
| Octapharma USA, Inc. | 1 | $17 |
| Ipsen Biopharmaceuticals, Inc | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
| Roche Diagnostics Corporation | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Secura Bio, Inc. | 1 | $12 |
How this compares
$5,480 in reported general payments places this provider in the 45th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JaypircaPirtobrutinib | 13 | $288,093 |
| Lenalidomide | 23 | $273,510 |
| LynparzaOlaparib | 14 | $199,693 |
| VerzenioAbemaciclib | 12 | $188,563 |
| SprycelDasatinib | 12 | $184,534 |
| KisqaliRibociclib Succinate | 11 | $151,923 |
| NubeqaDarolutamide | 12 | $151,051 |
| EliquisApixaban | 36 | $36,727 |
| Letrozole | 102 | $2,951 |
| Tamoxifen Citrate | 74 | $1,800 |
| Imatinib Mesylate | 15 | $1,247 |
| Ondansetron Hcl | 21 | $1,231 |
| Anastrozole | 45 | $897 |
| Potassium Chloride | 33 | $865 |
| Levofloxacin | 11 | $558 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCJaypirca, Verzenio, Olanzapine | $14 | $476,81539 claims |
| AstraZenecaLynparza | $124 | $199,69314 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $556 | $184,53412 claims |
| NovartisKisqali | $1,634 | $151,92311 claims |
| PfizerEliquis | $480 | $36,72736 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in Cameron Park
- Alain AlgaziSan Francisco$119.2M
- David BerzLos Angeles$43.3M
- Jonathan GoldmanSanta Monica$35.7M
- Omid HamidSanta Monica$23.7M
- Nicholas McAndrewLos Angeles$22.9M
- Aditya BardiaSanta Monica$22.1M
- Joseph TuscanoSacramento$20.4M
- Zev WainbergSanta Monica$19.3M
- Caitlin CostelloSan Diego$16.9M
- Rana McKaySan Diego$15.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.